Zimmer Biomet stock holds near its yearly range after Q1 2026 results

Zimmer Biomet (ISIN US98956P1021) stock is supported by Q1 2026 operating data that still frames the share story: net sales were $1.92 billion, adjusted EPS came in at $1.81, and adjusted diluted EPS was $1.81, according to the company's latest quarterly reporting. Those figures give investors a dated baseline for the orthopedic group's current valuation picture.

Q1 2026 shows the scale

The latest quarter also showed a 3.9% year-over-year sales increase on an as-reported basis, while constant-currency sales grew 3.5% in Q1 2026. That combination matters because it ties revenue progress to the period's currency backdrop rather than leaving the growth story unexplained.

Zimmer Biomet also reported adjusted EBITDA of $531.0 million for Q1 2026, with an adjusted EBITDA margin of 27.8%. The margin is the number that stands out for stockholders because it shows how much profit the company converted from its revenue base during the quarter.

Margin and growth

For the full-year 2026 framework, Zimmer Biomet guided to organic revenue growth of 3.5% to 4.5%, adjusted EPS of $8.05 to $8.25, and adjusted operating margin expansion of 50 to 75 basis points. That outlook gives the market a concrete range for earnings power and operating leverage in the current fiscal year.

In the quarter, the company also said it returned $97 million to shareholders through dividends and buybacks combined. That cash use is modest next to quarterly revenue, but it helps show how management is balancing growth, margins, and capital return in 2026.

Persona and procedure

Zimmer Biomet's business remains centered on hip, knee, shoulder, and surgical products, which makes procedure volumes and hospital demand the key operating link between product demand and reported revenue. The company said Q1 2026 sales benefited from broad-based volume trends, while its guidance implies a second-half test of whether that pace can continue.

That is why the current stock case is less about a single trading day and more about whether the 2026 ranges for revenue, EPS, and margin can all move in the same direction. The market now has three measurable anchors to watch: $1.92 billion in quarterly sales, $531.0 million in adjusted EBITDA, and $8.05 to $8.25 in full-year adjusted EPS guidance.

Orthopedics still matters

The company is still a pure-play orthopedic franchise, and that matters because the mix of reconstructive and surgical products typically shapes both pricing and margin trends. In Q1 2026, Zimmer Biomet's results showed that its earnings base remains sensitive to volume progress rather than only to financial engineering.

For investors, the most useful comparison is between the 3.5% constant-currency sales growth and the 50 to 75 basis points of full-year adjusted operating margin expansion. If revenue growth keeps translating into margin expansion, the 2026 guide becomes more credible; if not, the spread between sales and profit growth will be the first thing to compress.

Shares and valuation

Zimmer Biomet stock traded in a broad valuation context shaped by those Q1 2026 figures and the company's 2026 outlook. The stock's framing now depends on whether future reports can keep matching the quarter's 3.9% sales increase, 27.8% adjusted EBITDA margin, and $8.05 to $8.25 adjusted EPS guide.

That set of numbers makes the company easier to monitor than to guess about. The next material move in the story will come from whether the next quarter confirms the same pattern of revenue growth and margin discipline.